# Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

> **NCT04871646** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 586 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** CKD-314+SOC
- **DRUG:** CKD-314 Placebo+SOC

## Key facts

- **NCT ID:** NCT04871646
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2022-03
- **Final completion:** 2022-08
- **Target enrollment:** 586 (ESTIMATED)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871646, "Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04871646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*